The EXOC6 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Raji B lymphocyte line. This model employs CRISPR/Cas9-mediated gene disruption to generate a heterogeneous pool of EXOC6-deficient cells, serving as a loss-of-function tool for studying the exocyst complex in immune cell biology.
The Raji cell line is a lymphoblastoid B cell model isolated from a Burkitt lymphoma patient, characterized by EBV transformation and a hallmark MYC/IGH translocation. These suspension cells produce immunoglobulins and are widely employed to investigate B cell signaling, lymphoma pathogenesis, and therapeutic interventions due to their robust growth and well-characterized molecular features.
EXOC6 encodes Sec15, a core subunit of the exocyst complex responsible for tethering post-Golgi secretory vesicles to the plasma membrane. Its activity is governed by upstream regulators including RalA, RalB, and Arf6 GTPases, acting downstream of PI3K and growth factor receptors. Sec15 directly associates with exocyst partners SEC5, SEC3, SEC8, EXO70, and EXO84, and coordinates with vesicle SNARE proteins and actin regulators to facilitate polarized exocytosis. This machinery is essential for targeted secretion of cytokines and surface receptor delivery, processes critical for B cell activation and immune synapse formation.
In the Raji B cell context, EXOC6 knockout disrupts exocyst-dependent trafficking, impairing cytokine release and membrane protein localization. This provides a physiologically relevant system to dissect how defective secretion alters B cell receptor signaling, adhesion, and intercellular communication, and how such dysfunctions contribute to lymphoma progression and immune evasion.
Researchers can leverage this polyclonal population in a variety of assays: RT-qPCR and Western blotting for knockout confirmation, ELISA to quantify secreted cytokines, immunofluorescence and flow cytometry to analyze surface marker expression, co-immunoprecipitation to assess exocyst complex assembly, and B cell activation assays to evaluate functional outcomes. This product is a versatile platform for investigations into exocyst-mediated secretion in lymphocytes and for exploring trafficking-related mechanisms in cancer. For more information, please contact Ascent Research.
